Compare Quest Diagnostics Inc (DGX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KB Financial Group, Inc. — how do they compare? Quest Diagnostics Inc trades at $236.56 (market cap $26.21B), while KB Financial Group, Inc. trades at $117.76 (market cap $41.21B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| DGX | KB | |
|---|---|---|
Market Cap | $26.21B | $41.21B |
Sector | Health | Financials |
52-Week High | $238.50 | $124.01 |
52-Week Low | $173.49 | $77.50 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
KB Financial Group (KB) trades at $118.00, down 2.26% today, with a bullish technical signal from moving averages. The stock shows strong fundamental performance with consistent earnings beats, 27.82% net income margin, and attractive valuation at P/E of 10.36 and P/B of 0.98. Recent news highlights momentum potential and diversification into non-banking segments, which now contribute 43% of earnings.
Outlook remains positive with earnings growth and shareholder returns as key catalysts, though risks include volatile operating environment and heavy investing cash outflows. Analyst consensus leans cautious with 67% hold ratings, suggesting potential upside requires continued execution on diversification and fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
